碳青霉烯类与第三代头孢菌素经验性治疗自发性细菌性腹膜炎的比较
该回顾性研究纳入韩国7家转诊中心2013年9月至2018年1月连续865例首次自发性细菌性腹膜炎患者,比较碳青霉烯类与第三代头孢菌素经验性治疗的住院死亡率。整体两组住院死亡率无显著差异,但在CLIF-SOFA评分≥7的重症患者中碳青霉烯类与较低的住院死亡率相关。
要点
- 整体队列中碳青霉烯组与第三代头孢菌素组住院死亡率无显著差异(25.8% vs 25.3%)。
- CLIF-SOFA评分≥7的重症患者中,碳青霉烯组住院死亡率低于第三代头孢菌素组(23.1% vs 38.8%)。
- CLIF-SOFA评分较低的患者中,两组住院死亡率无显著差异(24.7% vs 16.0%)。
核心结论
- 对于首次自发性细菌性腹膜炎患者,碳青霉烯类经验性治疗与第三代头孢菌素相比未降低住院死亡率。
- 在重症患者(CLIF-SOFA评分≥7)中,碳青霉烯类经验性治疗与较低的住院死亡率显著相关。
研究设计与样本
- 回顾性研究,纳入韩国7家转诊中心2013年9月至2018年1月连续865例首次自发性细菌性腹膜炎患者,其中275例培养阳性,103例为第三代头孢菌素耐药细菌感染。
- 主要结局为住院死亡率,所有比较均采用经逆概率治疗加权平衡基线特征后的患者数据。
主要发现
- 初始接受经验性抗生素治疗的患者中,95例(11.0%)接受碳青霉烯类,655例(75.7%)接受第三代头孢菌素。
- 整个研究队列中,碳青霉烯组与第三代头孢菌素组住院死亡率无显著差异(25.8% vs 25.3%;aOR 0.97;95%CI 0.85-1.11;P=.66)。
- CLIF-SOFA评分≥7亚组(n=314)中,碳青霉烯组住院死亡率低于第三代头孢菌素组(23.1% vs 38.8%;aOR 0.84;95%CI 0.75-0.94;P=.002)。
- CLIF-SOFA评分较低亚组(n=436)中,碳青霉烯组与第三代头孢菌素组住院死亡率无显著差异(24.7% vs 16.0%;aOR 1.06;95%CI 0.85-1.32;P=.58)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Third-generation cephalosporins (TGCs) are recommended as first-line antibiotics for treatment of spontaneous bacterial peritonitis (SBP). However, antibiotics against multidrug-resistant organisms (such as carbapenems) might be necessary. We aimed to evaluate whether carbapenems are superior to TGC for treatment of SBP. METHODS: We performed a retrospective study of 865 consecutive patients with a first presentation of SBP (275 culture positive; 103 with TGC-resistant bacterial infections) treated at 7 referral centers in Korea, from September 2013 through January 2018. The primary outcome was in-hospital mortality. We made all comparisons using data from patients whose baseline characteristics were balanced by inverse probability of treatment weighting. RESULTS: Of patients who initially received empirical treatment with antibiotics, 95 (11.0%) received carbapenems and 655 (75.7%) received TGCs. Among the entire study cohort, there was no significant difference in in-hospital mortality between the carbapenem (25.8%) and TGC (25.3%) groups (adjusted odds ratio [aOR], 0.97; 95% CI, 0.85-1.11; P = .66). In the subgroup of patients with high chronic liver failure-sequential organ failure assessment (CLIF-SOFA) scores (score of 7 or greater, n = 314), carbapenem treatment was associated with lower in-hospital mortality (23.1%) than in the TGC group (38.8%) (aOR, 0.84; 95% CI, 0.75-0.94; P=.002). In contrast, among patients with lower CLIF-SOFA scores (n = 436), in-hospital mortality did not differ significantly between the carbapenem group (24.7%) and the TGC group (16.0%) (aOR, 1.06; 95% CI, 0.85-1.32; P = .58). CONCLUSIONS: For patients with a first presentation of SBP, empirical treatment with carbapenem does not reduce in-hospital mortality compared to treatment with TGCs. However, among critically ill patients (CLIF-SOFA scores ≥7), empirical carbapenem treatment was significantly associated with lower in-hospital mortality than TGCs.
引用
- Kim SW, Yoon JS, Park J, et al. Empirical Treatment With Carbapenem vs Third-generation Cephalosporin for Treatment of Spontaneous Bacterial Peritonitis. Clin Gastroenterol Hepatol. 2020. PMID: 32623007. doi:10.1016/j.cgh.2020.06.046
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。